The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus
Histopathology · 2026
DOI: 10.1111/his.70042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Pedro Genaro Delgado Guillena und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital de Mérida, Badajoz, Spain. Hauptthemen laut MEDLINE: Stomach Neoplasms, Gastritis, Precancerous Conditions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Spanish Society of Digestive Endoscopy, Spanish Association of Gastroenterology Spanish Association.
Abstract (Originalsprache)
Introduction
The risk stratification of gastric cancer (GC) is graded by assessing well‐established precursor lesions, glandular atrophy (GA), and intestinal metaplasia (IM), resulting in both the operative link on gastritis assessment (OLGA), and intestinal metaplasia (OLGIM) systems. Although the OLGIM stage is reproducible among pathologists, the OLGA system is laborious to calculate and has poor reproducibility. In addition, it does not comprehensively address the severity of both GA and IM as recommended by the Sydney consensus. We aimed to propose the Operative Link on Gastric Intestinal Metaplasia and Glandular Atrophy Assessment (OLGIMA) system, which identifies OLGIM III–IV and upstages 0–II with advanced GA.
Methods
A cross‐sectional study of consecutive diagnostic gastroscopies in adults was designed. Systematic gastric biopsies were taken. The updated Sydney guidelines were used for histological grading of GA and IM. Higher GC risk was defined as OLGIM III–IV and advanced GA.
Results
The OLGIMA stage was assessed based on the most severe GA and/or IM findings in both antrum and corpus. We included 998 patients (median age 57; 64% women; 35% Helicobacter pylori infection). Thirty‐nine (3.9%) patients had higher GC risk: 17 (1.7%) with OLGIM III–IV; 12 (1.2%) with advanced GA, and 10 (1%) meeting both criteria. Among OLGIM 0‐II, 12 (1.2%) patients had advanced GA. The OLGIMA system upstaged 39 (3.9%) patients to III–IV, being more sensitive than OLGIM.
Conclusions
The new OLGIMA system identifies patients at higher GC risk (OLGIMA III–IV), encompassing all OLGIM III–IV patients, and upstaging those OLGIM 0–II with advanced GA. This approach addresses the OLGA and OLGIM limitations by integrating GA and IM severity as recommended by the Updated Sydney consensus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hospital de Mérida, Badajoz, Spain.
- Department of Pathology, Hospital Clínic, Barcelona, Spain.
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- Facultat de Medicina i Ciències de la Salud, Universitat de Barcelona (UB), Barcelona, Spain.
- Gastroenterology Research Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.
ORCID-Profile: Pedro Genaro Delgado Guillena, Miriam Cuatrecasas, Sheyla Montori, Nayra Felipez Varela, Joan Llach, Iva Archilla, Pablo Florez-Diez, Eva Barreiro-Alonso, Javier Tejedor-Tejada, Raquel Vicente, Alaín Huerta, Silvia Patricia Ortega, Henar Nuñez, Oliver Patrón, Carolina Mangas, Diana Zaffalon, Luis Hernández, Gadea Hontoria, Gonzalo Hijos, Maria Jose Domper-Arnal, Sara Zarraquiños, Alberto Herreros De Tejada, Anabella Cuestas, Glòria Fernández-Esparrach, Leticia Moreira, Eduardo Albéniz
Förderung
- Instituto de Salud Carlos III
- Spanish Society of Digestive Endoscopy
- Spanish Association of Gastroenterology Spanish Association
Zitieren
APA
Delgado Guillena, P. G., Cuatrecasas, M., Montori, S., Felipez Varela, N., Llach, J., Archilla, I., Florez-Diez, P., Barreiro-Alonso, E., Tejedor-Tejada, J., Vicente, R., Soria, M. T., Huerta, A., Ortega, S. P., Nuñez, H., Patrón, O., Mangas, C., Zaffalon, D., Hernández, L., Yip, L. E., …, & EpiGASTRIC/EDGAR Consortium (2026). The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus. Histopathology. https://doi.org/10.1111/his.70042
Vancouver
Delgado Guillena PG, Cuatrecasas M, Montori S, Felipez Varela N, Llach J, Archilla I, et al. The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus. Histopathology. 2026. doi:10.1111/his.70042
BibTeX
@article{DelgadoGuillena2026,
author = {Delgado Guillena, Pedro Genaro and Cuatrecasas, Miriam and Montori, Sheyla and Felipez Varela, Nayra and Llach, Joan and Archilla, Iva and Florez-Diez, Pablo and Barreiro-Alonso, Eva and Tejedor-Tejada, Javier and Vicente, Raquel and Soria, M Teresa and Huerta, Alaín and Ortega, Silvia Patricia and Nuñez, Henar and Patrón, Oliver and Mangas, Carolina and Zaffalon, Diana and Hernández, Luis and Yip, Luis Enrique and Hontoria, Gadea and Hijos, Gonzalo and Domper-Arnal, Maria Jose and Zarraquiños, Sara and Herreros De Tejada, Alberto and Córdoba, Alicia and Cuestas, Anabella and Fernández-Esparrach, Glòria and Moreira, Leticia and Albéniz, Eduardo and EpiGASTRIC/EDGAR Consortium, EpiGASTRIC/EDGAR Consortium},
title = {The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus},
journal = {Histopathology},
year = {2026},
doi = {10.1111/his.70042}
}
EUVIMED